Skip to main content
. 2018 Apr 12;8:5922. doi: 10.1038/s41598-018-24020-y

Table 1.

G-CSF mobilization and coronary stenosis.

Control
(normal saline, 2 mL/d, n = 6)
Low-dose
(G-CSF, 2.5 μg/kg/d, n = 6)
Middle-dose
(G-CSF, 5 μg/kg/d n = 6)
High-dose
(G-CSF, 10 μg/kg/d, n = 6)
Distal segments of ameroid in LCX
4 weeks after modeling
Stenosis, % 97.2 ± 3.2 96.8 ± 5.0 96.6 ± 3.8 95.9 ± 3.7
8 weeks after modeling
Stenosis, % 98.8 ± 1.2 96.3 ± 2.1 87.8 ± 3.6*#†‡ 92.3 ± 4.5*#†
Proximal segments of ameroid in LCX
Before modeling
Diameter of referring segment, mm 2.19 ± 0.06 2.18 ± 0.06 2.22 ± 0.05 2.20 ± 0.04
Diameter of ameroid constrictor, mm 2.20 ± 0.04 2.16 ± 0.08 2.25 ± 0.08 2.18 ± 0.06
4 weeks after modeling
Diameter of referring segment, mm 2.18 ± 0.07 2.18 ± 0.04 2.21 ± 0.05 2.21 ± 0.06
Minimum diameter, mm 1.49 ± 0.18 1.46 ± 0.20 1.47 ± 0.12 1.50 ± 0.14
Stenosis, % 32 ± 5 33 ± 6 34 ± 5 32 ± 7
8 weeks after modeling
Diameter of referring segment, mm 2.19 ± 0.05 2.18 ± 0.07 2.21 ± 0.06 2.20 ± 0.07
Minimum diameter, mm 1.03 ± 0.14* 1.17 ± 0.10* 1.32 ± 0.12*#†‡ 1.19 ± 0.15*
Stenosis, % 52 ± 8* 46 ± 6* 41 ± 7*#†‡ 47 ± 6*

LCX, left circumflex artery.

*P < 0.05 compared with 4 weeks after modeling; #P < 0.05 compared with control group; P < 0.05 compared with low dose G-CSF therapy group; P < 0.05 compared with high dose G-CSF therapy group.